Dirk Lindenblatt

Dirk Lindenblatt

Auto-generated profile, based on publicly available information

Dirk Lindenblatt

Universität zu Köln, Department für Chemie und Biochemie, Institut für Biochemie, Zülpicher Straße 47, D-50674 Köln, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DLDirk Lindenblatt
Dirk Lindenblatt
VAVioletta Applegate
Violetta Applegate
ANAnna Nickelsen
Anna Nickelsen
Merlin Jan KlußmannMerlin Jan Klußmann
Merlin Jan Klußmann
Ines NeundorfInes Neundorf
Ines Neundorf
Karsten NiefindKarsten Niefind
Karsten Niefind

19 March 2019 in ACS Omega
Verified
Journal Article
Open access
DLDirk Lindenblatt
Dirk Lindenblatt
ANAnna Nickelsen
Anna Nickelsen
VAVioletta M. Applegate
Violetta M. Applegate
JHJennifer Hochscherf
Jennifer Hochscherf
BWBenedict Witulski
Benedict Witulski
Karsten NiefindKarsten Niefind
Karsten Niefind
CK2α and CK2α′ are the two isoforms of the catalytic subunit of human protein kinase CK2, an important target for cancer therapy. They have similar, albeit not identical functional and structural properties, and were occasionally reported to be inhibited with distinct efficacies by certain ATP-competitive ligands. Here, we present THN27, an indeno[1,2-b]indole derivative, as a further inhibitor with basal isoform selectivity. The selectivity disappears when measured using CK2α/CK2α′ complexes with CK2β, the regulatory CK2 subunit. Co-crystal structures of THN27 with CK2α and CK2α′ reveal that subtle differences in the conformational variability of the interdomain hinge region are correlated with the observed effect. In the case of CK2α′, a crystallographically problematic protein so far, this comparative structural analysis required the development of an experimental strategy that finally enables atomic resolution structure determinations with ab initio phasing of potentially any ATP-competitive CK2 inhibitor and possibly many non-ATP-competitive ligands as well bound to CK2α′.

20 February 2019 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
DLDirk Lindenblatt
Dirk Lindenblatt
MHMareike Horn
Mareike Horn
CGClaudia Götz
Claudia Götz
Karsten NiefindKarsten Niefind
Karsten Niefind
Ines NeundorfInes Neundorf
Ines Neundorf
MPMarkus Pietsch
Markus Pietsch

26 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DLDirk Lindenblatt
Dirk Lindenblatt
ANAnna Nickelsen
Anna Nickelsen
VAVioletta M. Applegate
Violetta M. Applegate
Joachim JoseJoachim Jose
Joachim Jose
Karsten NiefindKarsten Niefind
Karsten Niefind

25 November 2023 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
CWChristian Werner
Christian Werner
DLDirk Lindenblatt
Dirk Lindenblatt
KVKaido Viht
Kaido Viht
AUAsko Uri
Asko Uri
Karsten NiefindKarsten Niefind
Karsten Niefind
The structural knowledge about protein kinase CK2 is dominated by crystal structures of human CK2α, the catalytic subunit of human CK2, and the product of the CSNK2A1 gene. In contrast, far fewer structures of CK2α′, its paralogous isoform and the product of the CSNK2A2 gene, have been published. However, according to a PDB survey, CK2α′ is the superior alternative for crystallographic studies because of the inherent potential of the single mutant CK2α′Cys336Ser to provide crystal structures with atomic resolution. In particular, a triclinic crystal form of CK2α′Cys336Ser is a robust tool to determine high-quality enzyme-ligand complex structures via soaking. In this work, further high-resolution CK2α′Cys336Ser structures in complex with selected ligands emphasizing this trend are described. In one of these structures, the “N-terminal segment site”, a small-molecule binding region never found in any eukaryotic protein kinase and holding the potential for the development of highly selective substrate-competitive CK2 inhibitors, was discovered. In order to also address the binding site for the non-catalytic subunit CK2β, which is inaccessible in these triclinic CK2α′Cys336Ser crystals for small molecules, a reliable path to a promising monoclinic crystal form of CK2α′Cys336Ser is presented. In summary, the quality of CK2α′Cys336Ser as an exquisite crystallographic tool is solidified.

1 March 2025 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
CMChristelle Marminon
Christelle Marminon
CWChristian Werner
Christian Werner
AGAlexander Gast
Alexander Gast
LHLars Herfindal
Lars Herfindal
JCJohana Charles
Johana Charles
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
Protein kinase CK2 is a promising therapeutic target, especially in oncology. Over the years, various inhibitors have been developed, with polyhalogenated scaffolds emerging as a particularly effective class. Halogens like bromine and chlorine enhance inhibitor stability by forming additional interactions within the ATP pocket. Among halogenated scaffolds, benzotriazole and benzimidazole have led to potent molecules such as 4,5,6,7-tetrabromo-1H-benzotriazole (IC50 = 300 nM) and 4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazole (IC50 = 140 nM). Modifications, including 4,5,6-tribromo-7-ethyl-1H-benzotriazole (IC50 = 160 nM), further improved activity. Changing scaffolds while retaining halogens has enabled design of new inhibitors. Flavonols, dibenzofuranones, and the indeno[1,2-b]indole scaffold are key examples. Halogenation of the reference molecule 5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4b, IC50 = 360 nM) significantly boosted potency. The study focused on introducing four halogens, yielding to the compound 1,2,3,4-tetrabromo-5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (MC11), with an IC50 of 16 nM. Co-crystallography revealed how bromine atoms enhance binding, and MC11 demonstrated strong in cellulo activity, particularly against leukemic cell lines like IPC-Bcl2.